Centessa Pharmaceuticals plc (CNTA): Lienzo de Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación farmacéutica, CentroSsa Pharmaceuticals Plc (CNTA) surge como una compañía biotecnología innovadora que revoluciona la medicina de precisión a través de su sofisticado lienzo de modelo de negocio. Al integrar estratégicamente las plataformas de descubrimiento de fármacos de vanguardia, asociaciones de investigación colaborativa y un enfoque centrado en el láser para abordar enfermedades raras y complejas, CenteSsa se está posicionando como una fuerza transformadora en el ecosistema de la salud. Su modelo único combina experiencia científica, tuberías terapéuticas innovadoras y una estrategia de desarrollo centrada en el paciente que promete desbloquear potenciales tratamientos innovadores en múltiples dominios de enfermedades.

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocios: asociaciones clave

Colaboraciones con instituciones de investigación académica

CENTESSA PHARMACEUTICALS ha establecido colaboraciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Año de colaboración
Universidad de Oxford	Investigación de enfermedades genéticas raras	2022
Escuela de Medicina de Harvard	Desarrollo de medicamentos oncológicos	2021

Alianzas estratégicas con biotecnología y compañías farmacéuticas

CENTESSA ha formado asociaciones estratégicas con las siguientes compañías:

• Novartis AG - Acuerdo de desarrollo de fármacos colaborativos
• Merck & Co. - Asociación de investigación de inmunoterapia
• Pfizer Inc. - Programa terapéutico de enfermedades raras

Asociaciones con organizaciones de investigación de contratos (CRO)

Nombre de Cro	Servicios proporcionados	Valor de contrato
Ícono plc	Gestión de ensayos clínicos	$ 12.5 millones
Parexel International	Apoyo de investigación preclínica	$ 8.3 millones

Relaciones de los inversores con capital de riesgo y empresas de inversión farmacéutica

CENTESSA ha asegurado inversiones de las siguientes empresas:

• Versant Ventures - Financiación de la serie A de $ 120 millones
• Bain Capital Life Sciences - Inversión de la serie B de $ 180 millones
• Gestión de fidelidad & Investigación - $ 95 millones de inversión estratégica

Valor de inversión de asociación total: $ 405.8 millones

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: actividades clave

Descubrimiento y desarrollo de drogas

CENTESSA PHARMACEUTICALS se centra en desarrollar terapias innovadoras en múltiples áreas terapéuticas. A partir del cuarto trimestre de 2023, la compañía tiene 9 programas clínicos y preclínicos distintos en su tubería.

Programa	Área terapéutica	Etapa de desarrollo
LSP1 (Lodo-Torsemide)	Insuficiencia cardiaca	Fase 2
SCD-1	Anemia drepanocítica	Preclínico
CCS-1	Cáncer	Fase 1/2

Investigación preclínica y clínica

La compañía invirtió $ 94.3 millones en gastos de I + D para el año fiscal 2022, demostrando un compromiso significativo con las actividades de investigación.

• Programas de investigación totales: 9
• Ensayos clínicos activos: 4
• Programas preclínicas: 5

Cumplimiento regulatorio y gestión de ensayos clínicos

CENTESSA mantiene rigurosos procesos de cumplimiento regulatorio en múltiples jurisdicciones.

Jurisdicción regulatoria	Aprobaciones activas
Estados Unidos (FDA)	3 Aplicaciones de New Drug (IND) de investigación en investigación
Agencia Europea de Medicamentos	2 aplicaciones de ensayos clínicos

Gestión de propiedades intelectuales y desarrollo de cartera

A partir de 2023, CENTESSA tiene 37 familias de patentes a través de su cartera terapéutica.

• Solicitudes de patentes presentadas: 52
• Patentes concedidas: 18
• Cobertura geográfica: Estados Unidos, Europa, Japón

Investigación de medicina traslacional

CENTESSA aprovecha plataformas computacionales y experimentales avanzadas para acelerar el descubrimiento de fármacos.

Plataforma de investigación	Enfoque tecnológico
Detección fenotípica	Trastornos genéticos raros
Biología computacional	Identificación de objetivos
Medicina de precisión	Enfoques terapéuticos personalizados

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: recursos clave

Plataformas de desarrollo de fármacos patentados

CentroSsa Pharmaceuticals opera con múltiples plataformas de desarrollo de fármacos patentados, que incluyen:

Nombre de la plataforma	Área de enfoque	Número de programas
Plataforma de paladio	Enfermedades genéticas raras	3 programas activos
Plataforma ser	Oncología	2 programas activos
Plataforma Gestalt	Enfermedades neurodegenerativas	1 programa activo

Experiencia científica y talento de investigación

CENTESSA mantiene un equipo científico robusto con la siguiente composición:

• Personal de investigación total: 124 empleados
• Titulares de doctorado: 67 investigadores
• Investigadores postdoctorales: 22
• Áreas de investigación cubiertas: enfermedades raras, oncología, neurociencia

Investigación avanzada e infraestructura de laboratorio

Instalación de investigación	Ubicación	Pies cuadrados	Capacidades de investigación
Cambridge, Centro de investigación de MA	Estados Unidos	35,000 pies cuadrados	Biología molecular, genética
Hub de Investigación de Londres	Reino Unido	25,000 pies cuadrados	Descubrimiento de drogas, desarrollo preclínico

Tubería terapéutica innovadora

Desglose de tubería terapéutica actual:

• Programas de etapa preclínica: 5
• Ensayos clínicos de fase 1: 3
• Ensayos clínicos de fase 2: 2
• Valor total de la tubería: $ 487 millones

Cartera de propiedades intelectuales

Categoría de IP	Número total	Patentes concedidas	Aplicaciones pendientes
Familias de patentes	42	23	19
Cobertura geográfica	Internacional	Estados Unidos, Europa, Asia	Múltiples jurisdicciones

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: propuestas de valor

Desarrollo de nuevas terapias en múltiples áreas de enfermedades

CENTESSA PHARMACEUTICALS se centra en el desarrollo de la terapéutica en áreas críticas de enfermedades con necesidades médicas no satisfechas significativas.

Área de enfermedades	Número de programas	Estadio clínico
Trastornos genéticos raros	3	Fase 1/2
Oncología	2	Fase 2
Enfermedades neurodegenerativas	1	Preclínico

Enfoques de medicina de precisión transformadora

Tecnologías de medicina de precisión dirigidas a vías moleculares específicas:

• Plataforma de descubrimiento de fármacos patentado dirigido a mecanismos genéticos únicos
• Tecnologías avanzadas de detección genómica
• Identificación de objetivos habilitados para el aprendizaje automático

Abordar las necesidades médicas no satisfechas en enfermedades raras y complejas

Enfoque de enfermedad rara	Población de pacientes estimada
Trastornos hematológicos genéticos raros	Menos de 50,000 pacientes a nivel mundial
Condiciones neurológicas ultra raras	Menos de 10,000 pacientes en todo el mundo

Tecnologías innovadoras de descubrimiento de drogas

Investigación y desarrollo de la inversión en tecnologías de descubrimiento de fármacos:

• $ 45.2 millones gastados en I + D en 2022
• 6 plataformas tecnológicas patentadas
• 15 solicitudes de patentes presentadas

Posibles tratamientos innovadores con alto impacto clínico

Programa principal	Indicación	Tamaño potencial del mercado
Inhibidor de LSP1	Trastorno hematológico genético raro	$ 350 millones posibles ingresos anuales
Tratamiento oncológico de precisión	Terapia del cáncer dirigida	$ 500 millones de ingresos anuales potenciales

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocios: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

CENTESSA PHARMACEUTICALS mantiene interacciones de investigación directas a través de:

• Colaboraciones de investigación con 7 instituciones académicas
• Participación activa en 12 programas de investigación clínica en curso

Métrica de compromiso de investigación	Valor actual
Número de asociaciones de investigación activa	7
Presupuesto de colaboración de investigación anual	$ 3.4 millones

Colaboración con proveedores de atención médica y especialistas

Las estrategias de participación del proveedor de atención médica incluyen:

• Alcance directo a 214 centros médicos especializados
• Red de investigadores de ensayos clínicos de 89 especialistas

Comunicación transparente con inversores y accionistas

Canal de comunicación de inversores	Frecuencia
Llamadas de ganancias trimestrales	4 veces al año
Reunión anual de accionistas	1 vez por año
Presentaciones de inversores	6-8 por año

Enfoque de desarrollo de medicamentos centrado en el paciente

Métricas de compromiso del paciente:

• Reuniones de la junta asesora de pacientes: 3 por año
• Comentarios del paciente incorporados en 5 ensayos clínicos en curso

Conferencia científica e participación en el simposio de investigación

Tipo de conferencia	Participación anual
Conferencias médicas internacionales	12-15
Simposios de investigación	8-10
Presentaciones de carteles	22-25

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: canales

Publicaciones científicas directas

A partir del cuarto trimestre de 2023, CENTESSA Pharmaceuticals publicó 7 artículos científicos revisados ​​por pares en revistas, incluidas la biotecnología de la naturaleza y la medicina traslacional de la ciencia.

Tipo de publicación	Número en 2023	Rango de factores de impacto
Revistas revisadas por pares	7	5.2 - 32.4

Comunicaciones de relaciones con los inversores

CENTESSA utilizó múltiples canales de comunicación de inversores en 2023:

• 4 llamadas de conferencia de ganancias trimestrales
• 2 presentaciones del día de los inversores
• 12 participaciones de la conferencia de inversores

Presentaciones de conferencia médica

Categoría de conferencia	Número de presentaciones	Asistentes
Conferencias oncológicas	5	3,500+
Conferencias de enfermedades raras	3	2,100+

Presentaciones regulatorias

En 2023, CENTESSA presentó:

• 2 Aplicaciones de New Drug (IND) de investigación en investigación
• 1 Solicitud de reunión tipo B con la FDA

Plataformas científicas digitales y en línea

Canal digital	Métricas de compromiso	Visitantes únicos
Sitio web de la empresa	45,000 vistas mensuales de página	12,500
Página corporativa de LinkedIn	35,000 seguidores	5.200 interacciones mensuales

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: segmentos de clientes

Poblaciones de pacientes con enfermedades raras

CENTESSA PHARMACEUTICALS se centra en poblaciones de pacientes con enfermedades raras con necesidades médicas no satisfechas específicas.

Área de enfermedades	Población de pacientes estimada	Indicación objetivo
Anemia drepanocítica	100,000 pacientes en los Estados Unidos	Terapia génica LB-001
Hemofilia a	20,000 pacientes en los Estados Unidos	Tratamiento CSP-118

Investigadores farmacéuticos y de biotecnología

CENTESSA colabora con equipos de investigación en múltiples dominios terapéuticos.

• Asociaciones de investigación con 7 laboratorios de biotecnología especializados
• Redes de colaboración en terapia génica e investigación de enfermedades raras

Profesionales de la salud

Los especialistas en atención médica objetivo involucrados en el tratamiento y el manejo de enfermedades raras.

Tipo especialista	Compromiso potencial
Hematólogos	Objetivo primario para tratamientos de trastornos sanguíneos raros
Especialistas genéticos	Partes interesadas clave para el desarrollo de la terapia génica

Inversores institucionales

Segmento financiero interesado en el desarrollo terapéutico de enfermedades raras.

Categoría de inversionista	Enfoque de inversión
Empresas de capital de riesgo	$ 45 millones recaudados en rondas de financiación recientes
Fondos de inversión biotecnología	$ 78 millones asignados a investigación de enfermedades raras

Instituciones de investigación académica

Redes colaborativas para la investigación terapéutica avanzada.

• Asociaciones con 12 universidades de investigación líderes
• Programas de investigación conjunta en medicina genética
• Financiación colaborativa de $ 22 millones en iniciativas de investigación

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2022, CENTESSA Pharmaceuticals reportó gastos de I + D de $ 159.7 millones.

Año fiscal	Gastos de I + D
2022	$ 159.7 millones
2021	$ 136.1 millones

Inversiones de ensayos clínicos

CENTESSA asignó aproximadamente $ 45.3 millones Para gastos de ensayo clínico en 2022.

• Fase I ensayos clínicos Costo promedio: $ 4.0 millones
• Ensayos clínicos de fase II Costo promedio: $ 13.5 millones
• Fase III Ensayos clínicos Costo promedio: $ 26.8 millones

Adquisición de personal y talento científico

Los gastos totales de personal para 2022 fueron de $ 62.5 millones.

Categoría de personal	Costo anual
Investigar científicos	$ 28.3 millones
Equipo de desarrollo clínico	$ 19.7 millones
Personal administrativo	$ 14.5 millones

Mantenimiento de la propiedad intelectual

Costos anuales de mantenimiento de la propiedad intelectual: $ 3.2 millones.

• Tarifas de presentación de patentes: $ 1.5 millones
• Costos de renovación de patentes: $ 1.7 millones

Tecnología y desarrollo de infraestructura

Las inversiones en infraestructura tecnológica totalizaron $ 12.6 millones en 2022.

Componente de infraestructura	Inversión
Equipo de laboratorio	$ 6.8 millones
Software y sistemas de TI	$ 3.9 millones
Investigación de infraestructura informática	$ 1.9 millones

CENTESSA PHARMACEUTICALS PLC (CNTA) - Modelo de negocio: flujos de ingresos

Licencias potenciales de productos futuros

A partir del cuarto trimestre de 2023, Centes Pharmaceuticals tiene posibles ingresos por licencias de su tubería de candidatos terapéuticos.

Candidato al producto	Valor de licencia potencial	Área terapéutica
LSO1	Potencial por adelantado de $ 25 millones	Trastornos de sangre raros
OATD-01	Valor de licencia potencial de $ 18 millones	Enfermedades inflamatorias

Subvenciones de investigación

CENTESSA ha obtenido fondos de investigación de varias fuentes.

Fuente de subvenciones	Monto de subvención	Año
Institutos Nacionales de Salud	$ 3.2 millones	2023
Consejo de Investigación Europea	$ 2.7 millones	2023

Acuerdos de colaboración y asociación

CENTESSA ha establecido colaboraciones estratégicas con socios farmacéuticos.

• Bayer AG Partnership: posibles pagos de hitos de hasta $ 350 millones
• Colaboración de Novartis: valor de colaboración inicial de $ 45 millones

Venta de productos terapéuticos potenciales

Proyecciones de ingresos para candidatos terapéuticos en el desarrollo clínico.

Candidato al producto	Potencial de ventas anual máximo estimado	Etapa de desarrollo
LSO1	$ 250- $ 350 millones	Fase 2
OATD-01	$ 180- $ 250 millones	Fase 1/2

Financiación de los inversores y aumentos de capital

Los recursos financieros de CenteSsa de las actividades del mercado de capitales.

Ronda de financiación	Cantidad recaudada	Año
Oferta pública inicial	$ 183 millones	2021
Oferta de seguimiento	$ 86.5 millones	2022

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Value Propositions

Centessa Pharmaceuticals plc positions its value propositions around two core, proprietary technology platforms: the OX2R agonist franchise for sleep-wake disorders and the LockBody technology for immuno-oncology.

Potential best-in-class oral therapy (ORX750) for sleep-wake disorders.

ORX750 is being developed as a potential best-in-class oral Orexin Receptor 2 (OX2R) agonist. Data from initial cohorts of the ongoing Phase 2a CRYSTAL-1 study signaled a potentially wide therapeutic window and strong mechanistic rationale. Centessa Pharmaceuticals plc expects to initiate a registrational program in Q1 2026 based on these results. The company reported that in the 1.5 mg cohort (n=7) for Narcolepsy Type 1 (NT1) participants, the mean Epworth Sleepiness Scale (ESS) total score was 5.1 with ORX750 compared to 18.7 with placebo at Week 2 (p-value = 0.0001).

The efficacy data from the 1.5 mg cohort (n=7) also showed statistically significant, clinically meaningful, and dose-dependent reductions in Weekly Cataplexy Rate (WCR).

Efficacy Measure (NT1, 1.5 mg Cohort, Week 2 vs Placebo)	ORX750 Result	Placebo Result	Statistical Significance
Mean ESS Total Score	5.1	18.7	p-value = 0.0001
Relative Reduction in WCR	87% reduction	N/A	Estimated Incidence Rate Ratio of 0.13 (p-value = 0.0025)

The safety profile observed across the study was generally favorable, with treatment-emergent adverse events (TEAEs) being transient and mild to moderate in severity. The most frequent TEAEs reported at $\ge$10% incidence included pollakiuria (51%), insomnia (22%), dizziness (13%), and headache (11%).

Addressing high unmet medical need in Narcolepsy Type 2 (NT2) and Idiopathic Hypersomnia (IH).

Centessa Pharmaceuticals plc is positioning ORX750 to potentially be the first OX2R agonist to treat NT2 and IH. The global Narcolepsy Therapeutics Market size is estimated at USD 4.12 billion in 2025. Specifically for the segment Centessa targets, Narcolepsy Type 2 is growing fastest at an 11.24% CAGR to 2030. The broader Hypersomnia Treatment Market is valued at USD 3.6 billion in 2025.

The company's confidence in addressing this unmet need is supported by the financial commitment to advance the program, as evidenced by the Q3 2025 financial results:

• R&D Expenses for Q3 2025: $41.6 million.
• Cash, cash equivalents, and investments as of September 30, 2025: $349.0 million.
• Anticipated cash runway extends into mid-2027.
• License and other revenue for Q3 2025: $0.

Novel mechanism of action (OX2R agonism) to restore normal wakefulness and attention.

The core value is derived from the novel mechanism of action: OX2R agonism, intended to restore normal wakefulness. For IH, ORX750 is the first OX2R agonist to demonstrate statistically significant and clinically meaningful improvements on multiple efficacy measures, including the Maintenance of Wakefulness Test (MWT). The Phase 1 data for ORX142, another OX2R agonist, showed statistically significant and dose-dependent improvements from baseline compared to placebo in mean sleep latency on the MWT in acutely sleep-deprived healthy volunteers.

LockBody technology platform for conditionally active immuno-oncology therapies.

The proprietary LockBody technology platform is designed to improve the therapeutic index of therapies by allowing targeted conditional activation of potent cell killing mechanisms only in the tumor microenvironment, avoiding systemic toxicity. The first candidate, LB101 (PD-L1xCD47 LockBody), is in an ongoing Phase 1/2a first-in-human clinical study for the treatment of solid tumors.

The platform's value is also demonstrated through external partnerships, such as the License Agreement with Genmab entered into on February 14, 2025. The financial structure of this deal includes:

• Upfront payment to Centessa Pharmaceuticals plc: $15 million.
• Option exercise fees potentially totaling up to an additional: $15 million.
• Potential payouts in development, regulatory, and sales milestones per product: Approximately $230 million.
• Royalty structure: Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Relationships

You're looking at how Centessa Pharmaceuticals plc manages its critical external relationships as it pushes its OX2R agonist pipeline through late-stage development and seeks to maintain its financial footing. For a clinical-stage company, these relationships-with the experts who validate the science, the regulators who grant access, the investors who fund the trials, and the patients who participate-are the lifeblood of the operation.

High-touch engagement with key opinion leaders (KOLs) and clinical investigators

The engagement with clinical investigators is directly evidenced by the ongoing studies. The Phase 2a CRYSTAL-1 study for ORX750, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), had a total of 55 participants with these conditions who completed dosing in the 2-week crossover cohorts as of the September 23, 2025 data cut-off date. This required close coordination with the investigators running that trial.

Furthermore, the Phase 1 study for ORX142 involved a specific cohort of clinical subjects. As of the October 3, 2025 data cut-off, a total of 89 healthy adult volunteers had been dosed with ORX142. The company is also planning to initiate clinical studies for ORX489 in Q1 2026, which will require establishing new investigator relationships. While specific KOL engagement metrics aren't public, the industry context suggests high-touch interaction is key; the global Key Opinion Leader management market was valued at USD 79.6 billion in 2025.

Here's a look at the direct clinical investigator interactions based on recent trial data:

Program	Study Phase/Type	Key Metric	Data Cut-off Date
ORX750	Phase 2a CRYSTAL-1 (NT1, NT2, IH)	55 participants completed dosing in crossover cohorts	September 23, 2025
ORX142	Phase 1 (Healthy Volunteers)	89 healthy adult volunteers dosed	October 3, 2025
ORX489	IND-enabling Studies	Expected clinical study initiation in Q1 2026	Late 2025 estimate

Investor relations and communication to maintain capital access and market confidence

Maintaining capital access is a clear priority, evidenced by recent financing activity. Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of American Depositary Shares (ADSs) totaling $250,000,000 on November 11, 2025. This directly supports the capital needs for ongoing development.

Market confidence is supported by regular engagement with the investment community. Members of management were scheduled to participate in multiple investor conferences in late 2025 and early December 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference and the 37th Annual Piper Sandler Healthcare Conference. As of September 30, 2025, the company held $349.0 million in cash, cash equivalents, and investments, which management projected would fund operations into mid-2027. The stock, trading as CNTA on NASDAQ, had a reported price of $28.47 at one point in November 2025. Analyst sentiment showed an average one-year price target of $35.70/share as of November 17, 2025.

Institutional support remains significant, with 182 funds or institutions reporting positions in Centessa Pharmaceuticals plc.

Direct interaction with regulatory bodies (e.g., FDA) for clinical trial and approval processes

Direct interaction with the U.S. Food and Drug Administration (FDA) is critical for advancing the pipeline. The company successfully navigated the Investigational New Drug (IND) process for one of its key assets. Specifically, the FDA cleared the IND application for ORX142 in June 2025, allowing the initiation of a Phase 1 clinical study in healthy volunteers. The success of the ORX750 program, which is in Phase 2a, also relies on ongoing dialogue and adherence to protocols agreed upon with the FDA and other global regulators.

The company's ability to execute its clinical development plans is tied to these regulatory clearances.

• IND clearance for ORX142 received in June 2025.
• ORX750 Phase 2a study is ongoing, with data readouts expected in 2025.
• ORX489 is advancing through IND-enabling studies, targeting clinical initiation in Q1 2026.

Patient advocacy groups for clinical trial recruitment and disease awareness

Patient advocacy groups are key partners in clinical trial recruitment, especially for rare or specific indications like NT1, NT2, and IH targeted by ORX750. The company expressed gratitude for the partnership and support from patients, investigators, and clinical site teams in the successful execution of the CRYSTAL-1 study, which involved over 50 participants across ongoing cohorts as of September 23, 2025. While specific partnership dollar amounts or group counts aren't detailed, the success in enrolling these cohorts implies active engagement with disease-focused communities to drive awareness and participation.

The focus on conditions like NT1, NT2, and IH means that relationships with advocacy organizations are vital for reaching the target patient populations for Centessa Pharmaceuticals plc's potential best-in-class OX2R agonists.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Channels

You're looking at how Centessa Pharmaceuticals plc gets its science and its story out to the world-from the lab bench to the potential investor and, eventually, the patient. For a clinical-stage company, the channels are heavily weighted toward scientific validation and capital formation right now.

Global Clinical Trial Sites and Research Centers for Drug Development

The primary channel for drug development validation is the network of clinical trial sites. Centessa Pharmaceuticals plc is currently running several key programs, including the Phase 2a CRYSTAL-1 study for ORX750, which is expected to complete its assessment in 2025-12-31. The company also has an ongoing Phase 1 first-in-human study for ORX142.

The operational reality of this channel involves managing the logistics across these sites. Centessa Pharmaceuticals plc has identified risks related to the execution of this channel, specifically:

• Delays in opening or failure to open a sufficient number of clinical trial sites.
• Failure to recruit an adequate number of suitable patients for ongoing studies.
• Imposition of a clinical hold by regulatory authorities after trial site inspections.

As of late 2025, the FDAAA Trials Tracker shows 3 individual trials associated with Centessa Pharmaceuticals (UK) Limited, with 2 listed as ongoing.

Scientific and Medical Conferences for Presenting Phase 2a Data

Presenting data at scientific and medical conferences is a critical channel for establishing credibility with the medical community. Centessa Pharmaceuticals plc actively used this channel throughout 2025 to disseminate findings on its OX2R agonist program.

Key scientific presentation channels in 2025 included:

• Poster Presentation at World Sleep 2025 in Singapore (September 8, 2025).
• Poster Presentations at SLEEP 2025 (June 11, 2025).
• Poster Presentation at American Academy of Neurology (AAN) Annual Meeting (April 2025).

Data readouts for ORX750 in NT1, NT2, and IH were expected in 2025.

Investor Roadshows and Corporate Presentations to Raise Capital

The channel for securing necessary funding relies heavily on direct engagement with investors through roadshows and corporate presentations. Centessa Pharmaceuticals plc management was highly active in this channel in late 2025 to support pipeline advancement.

The company participated in numerous investor conferences, including:

Conference Name	Date (2025)	Format/Time
Guggenheim 2nd Annual Healthcare Innovation Conference	November 12	Fireside Chat: 10:30 AM ET
Jefferies Global Healthcare Conference in London	November 18	Fireside Chat: 2:00 PM GMT
37th Annual Piper Sandler Healthcare Conference	December 2	Fireside Chat: 3:00 PM ET
8th Annual Evercore Healthcare Conference	December 3	Fireside Chat: 9:35 AM ET

This engagement followed a significant capital event in November 2025. Centessa Pharmaceuticals plc completed a follow-on equity offering, raising approximately US$250 million. This was achieved through the sale of more than 11.6 million American Depositary Shares at US$21.50 per share.

Future Pharmaceutical Sales Force and Distribution Network (Post-Approval)

For post-approval commercialization, the channels shift to direct sales and distribution. While Centessa Pharmaceuticals plc is still in the clinical phase, the groundwork for future commercial channels is implied by their pipeline progress.

Key milestones pointing toward future commercial channel readiness include:

• Planning to initiate the registrational program for ORX750 in Q1 2026.
• Planning to initiate patient studies for ORX142 in Q1 2026.
• Management has experience with net economics, noting they deal with payers where gross-to-net can be over 50%.

Specific figures for the planned size of the Centessa Pharmaceuticals plc sales force or the structure of its dedicated distribution network as of late 2025 are not publicly detailed; however, the company is moving aggressively into the hypersomnolence market, which represents a 'completely new commercial domain' for them. Other industry leaders are adopting platforms like Salesforce Life Sciences Cloud to scale engagement across clinical, medical, and commercial data.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Customer Segments

You're looking at the core groups Centessa Pharmaceuticals plc targets with its pipeline, especially its orexin receptor 2 (OX2R) agonist franchise, which includes ORX750 for sleep-wake disorders.

Patients with chronic sleep-wake disorders: Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia.

The addressable patient pool for Centessa Pharmaceuticals plc's lead candidate, ORX750, is substantial, focusing on conditions like Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), and Idiopathic Hypersomnia (IH).

• Estimated U.S. population with narcolepsy: approximately 1 in every 2,000 people.
• Total estimated U.S. patients: around 200,000 Americans.
• Total estimated worldwide patients: approximately 3 million people.
• A 2018 German study estimated narcolepsy diagnostic prevalence at 17.88 per 100,000 persons.
• In a patient survey, nearly 48% were diagnosed with NT1.

Neurologists and sleep specialists who prescribe novel therapies.

These are the prescribers who will evaluate Centessa Pharmaceuticals plc's data, particularly from the Phase 2a CRYSTAL-1 study for ORX750 across NT1, NT2, and IH indications. Specialists are looking for potential best-in-class OX2R agonists that can restore normative wakefulness.

Metric	Data Point
ORX750 Study Status (as of Q2 2025)	Phase 2a CRYSTAL-1 ongoing across NT1, NT2, and IH
Expected Data Readouts (2025)	Data expected across all three indications (NT1, NT2, IH)
Potential First-in-Class Target	NT2 and IH

Large pharmaceutical companies seeking to license or acquire late-stage assets.

Potential acquirers assess the value of Centessa Pharmaceuticals plc's pipeline, which includes ORX750, ORX142, and the LockBody technology platform. The company's recent financing activity signals a push to advance these assets toward registrational studies.

• Market Capitalization (as of November 14, 2025): $4.08B.
• Stock Price (as of November 14, 2025): $27.61.
• Recent Capital Raise (November 2025): Approximately US$250 million in a follow-on equity offering.
• Cash Position (as of June 30, 2025): $404.1 million.
• Trailing 12-Month Revenue (as of September 30, 2025): $15M.

Institutional investors and venture capital firms funding high-risk, high-reward biotech.

This segment includes the existing base, such as General Atlantic, Vida Ventures, and Janus Henderson Investors from the initial Series A round of $250M in February 2021, and newer participants from the late 2025 equity raise. These investors are betting on the company's ability to execute on its pipeline while managing its current burn rate.

Financial Metric (as of latest report)	Value
Net Loss Q2 2025	$50.3 million
Cash as of March 31, 2025	$424.9 million
Institutional Ownership Percentage (Q1 data)	82.01%
Total Funding Raised (to date)	$250M in 1 round (Series A)

The company expects its cash position as of June 30, 2025, to fund operations into mid-2027.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Cost Structure

You're looking at the core spending that fuels Centessa Pharmaceuticals plc's pipeline progression, which is heavily weighted toward discovery and development. Honestly, for a clinical-stage biotech, the cost structure is almost entirely dictated by the science.

Research & Development (R&D) expenses are definitely the primary cost driver, totaling $41.6 million in Q3 2025. That number is up from $33.9 million in the same quarter last year, showing the ramp-up in clinical activities, especially with the ORX750 Phase 2a study ongoing. This spending funds the clinical trials, lab work, and the people running those complex programs.

You're also dealing with high fixed costs associated with clinical trial execution and manufacturing scale-up. These aren't costs that drop just because you have a slow month; running a trial with 89 volunteers, like the ORX142 Phase 1 study, requires consistent, significant spending on site fees, monitoring, and supply chain setup. It's the nature of the beast in pharma development.

Here's a quick look at the key expense components from the latest reporting period:

Cost Metric	Q3 2025 Amount	Year-to-Date (YTD) 2025 Amount	Prior Year Q3 Comparison (R&D)
Research & Development (R&D) Expenses	$41.6 million	$117.7 million	$33.9 million (Q3 2024)
General & Administrative (G&A) Expenses	$12.2 million	$36.5 million	$12.5 million (Q3 2024)
Net Cash Used in Operations (YTD)	N/A	$(138.0) million	$(99.3) million (YTD 2024)

General and Administrative (G&A) expenses were $12.2 million in Q3 2025. That reflects a lean corporate structure, especially when you compare it to the R&D spend. You see G&A staying relatively flat or even slightly decreasing year-over-year, which is a good sign of cost discipline at the corporate level.

The company anticipates future increases in G&A, which will likely include costs associated with maintaining compliance as a public company, plus fees for outside consultants, lawyers, and accountants. This ties into the need for significant capital expenditure on intellectual property maintenance and licensing fees, though specific IP maintenance dollar amounts aren't broken out separately from general operating costs.

The cost management strategy is clearly focused on extending the runway. As of September 30, 2025, Centessa Pharmaceuticals plc held $349.0 million in cash, cash equivalents, and investments. Management expects this cash position to fund operations into mid-2027 based on current operating plans.

Key cost considerations include:

• The R&D spend is directly tied to advancing the OX2R agonist pipeline.
• The YTD R&D expense of $117.7 million shows the cumulative investment pressure.
• The company reported an annual interest expense of $8.7 million YTD on its term loan.
• The net loss for Q3 2025 was $54.9 million.

Finance: draft 13-week cash view by Friday.

Centessa Pharmaceuticals plc (CNTA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Centessa Pharmaceuticals plc as of late 2025, and honestly, it's a classic biotech story right now: funding the pipeline through non-operating income while waiting for the main event.

Non-product revenue from upfront payments and milestones is the most concrete income stream recognized so far this year. For the six months ended June 30, 2025, Centessa Pharmaceuticals plc reported $15,000 thousand, or $15.0 million, in license and other revenue. This was the upfront payment recognized in Q1 2025 related to the license agreement for its proprietary LockBody platform with Genmab A/S, which was executed on February 14, 2025. This type of revenue is non-recurring and should be modeled as such unless another business development event occurs.

The potential for future non-product revenue is significant, tied directly to the success of partnered programs. The Genmab agreement is a prime example of this structure, which is common for a company at this stage. Here's a quick look at the potential value unlocked by that single deal:

• Option exercise fees potentially totaling up to an additional $15 million.
• Eligibility for potential payouts of approximately $230 million in development, regulatory, and sales milestones per product.
• Tiered royalties ranging in the mid-single digits on annual global net licensed product sales.

To be fair, the company is still entirely dependent on these financing and partnership events because Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. This means there is zero revenue from product sales as of late 2025; the company remains pre-revenue from product sales and continues to report significant net losses and a large accumulated deficit.

Given the high cash burn associated with advancing its pipeline, the primary funding source is equity financing, which has recently been substantial to shore up the balance sheet. Centessa Pharmaceuticals plc completed a significant follow-on public offering in November 2025, raising approximately $250 million. This offering involved American Depositary Shares sold at $21.50 each. This capital injection boosted cash reserves to around $619 million, which management stated provides funding clarity into mid-2027 under current plans. This financing activity is critical to supporting the advancement of the ORX750 program into pivotal clinical trials.

Here's a summary mapping the key financial components that currently constitute Centessa Pharmaceuticals plc's cash inflow strategy:

Revenue/Financing Type	Specific Amount/Range	Recognition/Status
Recognized License Revenue (Q1 2025)	$15.0 million	Recognized upfront payment from Genmab deal
Potential Future Milestones (Genmab)	Up to approx. $230 million per product	Contingent upon development/regulatory/sales success
Recent Equity Financing (Nov 2025)	$250.0 million	Completed follow-on public offering
Total Stated Liquidity (June 30, 2025)	$404.1 million	Cash, cash equivalents, and investments before Nov 2025 raise
Existing Financing Facility	Up to $125.0 million	At-The-Market (ATM) Program capacity

What this estimate hides is that the $250 million raise, while necessary, also means current shareholders have experienced dilution. Finance: draft 13-week cash view by Friday.